- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01581073
PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease (PREDICT)
April 17, 2018 updated by: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Prevention of End Stage Kidney Disease by Darbepoetin Alfa In CKD Patients With Non-diabetic Kidney Disease
The purpose of this study is to ask whether treating non-diabetic chronic kidney disease (CKD) patients with GFR 8-20mL/min/1.73m2
by darbepoetin Alfa targeting Hb between 11.0 and 13.0g/dL preserves renal function better than targeting Hb between 9.0 and11.0g/dL.
The investigators also ask whether the higher Hb targeting 11 to 13g/dL will not cause higher adverse events regarding cardiovascular diseases compared with lower Hb targeting 9 to 11g/dL.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Anemia is common among patients with chronic kidney disease (CKD) and is associated with an increased risk of cardiovascular and renal events.
Although erythropoiesis stimulating agent (ESA) has been used to correct anemia, use of ESA (hemoglobin level at approximately 13 g/dL) did not reduce cardiovascular or renal events in diabetic CKD patients.
Subgroup analysis of a recent randomized study suggested that use of darbepoetin alfa targeting Hb between 11 and 13 g/dL may preserve renal function better than targeting Hb between 9 and 11g/dL in non-diabetic CKD patients.
Study Type
Interventional
Enrollment (Actual)
476
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Tokyo
-
Shinagawa, Tokyo, Japan
- Showa University School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 85 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- CKD patients who have not received chronic dialysis
- eGFR 8 and more and less than 20 mL/min/1.73m2 determined twice in last 12 weeks.
- CKD patients with renal anemia at Hb less than 10g/dL within last 8 weeks
- CKD patients with TSAT 20% and higher or serum ferritin 100ng/mL and higher.
- CKD patients treated with standard care
- CKD patients provided written informed consent.
Exclusion Criteria:
- Diabetes (treated, or HbA1c 6.4% IFCC)
- CKD patients treated with ESA other than epoetins and darbepoetin.
- CKD patients treated with epoetin 24000 IU/4w or more.
- CKD patients treated with darbepoetin 90μg/4w or more.
- Uncontrolled hypertension (180/10mmHg and higher)
- Heart failure (NYHA III and IV)
- malignancy, hematological disorder
- malnutrition
- Active and continuous gastrointestinal tract bleeding
- ANCA associated glomerulonephritis, acute infection, active SLE
- CKD patients who will undergo dialysis or receive transplantation within 6 months
- Myocardial infarction within last 6 months
- Stroke or pulmonary embolism within last 12 months
- Severe allergy
- Pregnant women, women on lactation, or CKD patients who plant to get pregnant
- Allergy against erythropoetin
- Ineligible patients according to the investigator's judgment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: High Hb group
Darbepoetin alfa is given to the patients.
Target Hb level is 12.0g/dL and it should be maintained greater than or equal to 11.0g/dL and less than 13.0g/dL.
If the patients do not have medical history of myocardial infarction, stroke, pulmonary embolism, unstable angina, or peripheral artery disease, the target Hb level will be greater than or equal to 12.0g/dL and less than 13.0g/dL.
Maximum dose of darbepoetin alfa is 240 microgram per 4 weeks.
|
Darbepoetin alfa is used for targeting Hb level of 11-13g/dL in high Hb group, and 9-11g/dL in low Hb group.
|
ACTIVE_COMPARATOR: Low Hb group
Darbepoetin alfa is given to the patients.
Target Hb level is 10.0g/dL and it should be maintained greater than or equal to 9.0g/dL and less than 11.0g/dL.
If the Hb level exceeds 10.0g/dL in patients, reduce the dose amount or stop giving dose.
|
Darbepoetin alfa is used for targeting Hb level of 11-13g/dL in high Hb group, and 9-11g/dL in low Hb group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Composite renal outcome of chronic dialysis, kidney transplantation, eGFR 6 mL/min/1.73m2 or less, or eGFR less than 50% of initial value.
Time Frame: 96 weeks
|
96 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Composite cardiovascular outcome of cardiovascular death, stroke, myocardial infarction, leg amputation, admission by heart failure or angina.
Time Frame: 96 weeks
|
96 weeks
|
Time from enrollment to initiation of dialysis
Time Frame: 96 weeks
|
96 weeks
|
Time from enrollment to 50% reduction of eGFR from initial value
Time Frame: 96 weeks
|
96 weeks
|
Time from enrollment to death by any cause
Time Frame: 96 weeks
|
96 weeks
|
Change of eGFR from enrollment
Time Frame: 96 weeks
|
96 weeks
|
Change of proteinuria/Cr ratio
Time Frame: 96 weeks
|
96 weeks
|
Renal protection in patients who maintained the target Hb more than half the time
Time Frame: 96 weeks
|
96 weeks
|
50% renal survival
Time Frame: 96 weeks
|
96 weeks
|
Stroke
Time Frame: 96 weeks
|
96 weeks
|
Myocardial infarction
Time Frame: 96 weeks
|
96 weeks
|
Development of malignancy
Time Frame: 96 weeks
|
96 weeks
|
Number of Participants with Adverse Events baseline
Time Frame: 96 weeks
|
96 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Hayashi T, Maruyama S, Nangaku M, Narita I, Hirakata H, Tanabe K, Morita S, Tsubakihara Y, Imai E, Akizawa T; PREDICT Investigators. Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial. Clin J Am Soc Nephrol. 2020 May 7;15(5):608-615. doi: 10.2215/CJN.08900719. Epub 2020 Apr 3.
- Imai E, Maruyama S, Nangaku M, Hirakata H, Hayashi T, Narita I, Kono H, Nakatani E, Morita S, Tsubakihara Y, Akizawa T. Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial). Clin Exp Nephrol. 2016 Feb;20(1):71-6. doi: 10.1007/s10157-015-1133-z. Epub 2015 Jun 17.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
February 16, 2012
Primary Completion (ACTUAL)
December 7, 2017
Study Completion (ACTUAL)
December 7, 2017
Study Registration Dates
First Submitted
April 16, 2012
First Submitted That Met QC Criteria
April 18, 2012
First Posted (ESTIMATE)
April 19, 2012
Study Record Updates
Last Update Posted (ACTUAL)
April 18, 2018
Last Update Submitted That Met QC Criteria
April 17, 2018
Last Verified
April 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TRIGU1115
- UMIN000006616 (REGISTRY: UMIN Clinical Trials Registry)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRecruitingDiabetes Complications | Type 2 Diabetes | Maturity-Onset Diabetes of the Young (MODY)Taiwan
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
Oregon State UniversitySanofiCompletedType I or Type II Diabetes (Excludes Gestational Diabetes)
-
Zhejiang Provincial People's HospitalNot yet recruitingType2 Diabetes | type1diabetesChina
Clinical Trials on Darbepoetin alfa
-
AmgenCompletedAnemia | Non-Myeloid Malignancies
-
The Hospital for Sick ChildrenCompletedKidney Failure, ChronicCanada
-
AmgenCompleted
-
University of New MexicoUniversity of UtahCompletedHypoxic-Ischemic Encephalopathy Mild | Neonatal EncephalopathyUnited States
-
Kyowa Kirin Co., Ltd.Completed
-
AmgenCompletedLymphoma | Breast Neoplasms | Lung Neoplasms | Multiple Myeloma | Chronic Lymphocytic Leukemia